 |
|
|||||
Dr. Airriess has a Biomedical PhD and extensive experience with emerging companies and the challenges that face them, including fund-raising and the FDA approval process. He has a Ph.D. in cardiovascular physiology and has conducted post-doctoral studies in the Laboratory of Molecular Signaling, University of Cambridge, UK and the University of Sydney, Australia. He oversees day-to-day operations and is an active member of the CSC Board of Directors. Dr. Airriess has guided company operations through startup into the pre-clinical development phase of several therapeutic candidates, helping to position California Stem Cell to be a leader in cell based therapeutics. He has also served recently as Vice President of Product Development for biomedical device company CorTechs Labs, Inc, in La Jolla, CA, participating in fund-raising as well as product development activities including the FDA approval for marketing of diagnostic software. He was assistant professor of molecular endocrinology at the University of British Columbia and, prior to joining California Stem Cell, was Director of Scientific Computing for the National Center for Microscopy and Imaging Research and the Biomedical Informatics Research Network, both headquartered at the University of California, San Diego. Dr Airriess has served as Director of Operations and on the board of directors of a prominent multinational communications security firm, assisted in the start-up of several technology companies and served as technical advisor to investment houses Canaccord Capital Inc, Yorkton Securities (Toronto) and Hycroft Financial Partners (Seattle). His unique position as an expert in biomedical research as well as information technology and operations gives Dr. Airriess the perspective needed to successfully manage the practical challenges facing emerging biotechnology companies and help them grow and thrive. |
|
|||||
